Systemic Therapy of Advance/Metastatic Breast - Cancer Current Evidence and Future Concepts

被引：26

作者：

Liedtke, Cornelia ^{[1
]}

Kolberg, Hans-Christian ^{[2
]}

机构：

[1] Univ Hosp Schleswig Holstein, Dept Gynecol & Obstet, Campus Lubeck Ratzeburger Allee 160, D-23538 Lubeck, Germany

[2] Marienhosp Bottrop, Dept Gynecol & Obstet, Bottrop, Germany

来源：

BREAST CARE | 2016年 / 11卷 / 04期

关键词：

Metastatic breast cancer; Molecular breast cancer subgroups; Chemotherapy; Targeted therapy; Endocrine therapy; Clinical trials;

D O I：

10.1159/000447549

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Systemic therapy of metastatic breast cancer may include chemotherapy, endocrine therapy, and targeted therapies (e.g., antibody-based approaches). These agents may be employed alone or in combination based on the patient's breast cancer subtype. Therefore, characterization of the disease phenotype is necessary and may include biopsy of the metastatic site. Novel therapeutic approaches include immunologic therapies, PARP inhibitors, PI3K inhibitors, and CDK4/6 inhibitors, which are currently under investigation in clinical trials. (C) 2016 S. Karger GmbH, Freiburg.

引用

页码：275 / 281

页数：7